ABIVAX
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Abivax is a clinical-stage biotechnology company that develops therapeutics for chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms. The company's core innovation lies in its novel approach to microRNA biology. Its lead drug candidate, obefazimod, is a first-in-class, orally administered small molecule designed to enhance the expression of miR-124, a natural regulator of the inflammatory response. Obefazimod is in late-stage clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). Abivax's pipeline includes exploring obefazimod for other inflammatory indications and developing follow-on compounds from its proprietary chemical library.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-24 09:36 |
Major Shareholding Notification
Franchissement de seuils
|
French | 126.8 KB | ||
| 2025-10-15 18:00 |
Declaration of Voting Results & Voting Rights Announcements
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 20.8 KB | ||
| 2025-10-09 15:53 |
Major Shareholding Notification
Franchissement de seuil
|
French | 115.1 KB | ||
| 2025-10-06 10:00 |
Regulatory News Service
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Re…
|
English | 15.0 KB | ||
| 2025-10-05 17:00 |
Regulatory News Service
Abivax annonce la presentation des derniers resultats de l'essai ABTECT de 8 se…
|
French | 28.9 KB | ||
| 2025-10-03 11:54 |
Major Shareholding Notification
Franchissement de seuil
|
French | 119.6 KB | ||
| 2025-09-29 22:05 |
Regulatory News Service
Abivax annonce lacceptation dun late-breaking abstract supplementaire sur les…
|
French | 33.6 KB | ||
| 2025-09-23 22:05 |
Regulatory News Service
Abivax annonce la presentation des dernieres donnees sur obefazimod issues des …
|
French | 34.3 KB | ||
| 2025-09-16 18:00 |
Declaration of Voting Results & Voting Rights Announcements
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 20.7 KB | ||
| 2025-09-16 09:59 |
Major Shareholding Notification
Franchissement de seuil
|
French | 121.4 KB | ||
| 2025-09-12 17:45 |
Regulatory News Service
Abivax intègrera les indices CAC Mid 60 et SBF 120 suite à la révision annuelle…
|
French | 160.0 KB | ||
| 2025-09-12 17:45 |
Regulatory News Service
Abivax integrera les indices CAC Mid 60 et SBF 120 suite a la revision annuelle…
|
French | 21.0 KB | ||
| 2025-09-12 17:45 |
Regulatory News Service
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual R…
|
English | 8.6 KB | ||
| 2025-09-08 22:00 |
Earnings Release
Abivax Presents First Half 2025 Financial Results
|
English | 24.2 KB | ||
| 2025-09-02 10:55 |
Major Shareholding Notification
Franchissement de seuil
|
French | 121.8 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
